We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+52.39%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$498M
AUM Growth
+$154M
Cap. Flow
+$62.8M
Cap. Flow %
12.62%
Top 10 Hldgs %
81.5%
Holding
55
New
24
Increased
13
Reduced
1
Closed
6

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.2M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$11.6M
3
MRK icon
Merck
MRK
+$6.16M
4
IRON icon
Disc Medicine
IRON
+$5.64M
5
CYTK icon
Cytokinetics
CYTK
+$4.44M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$3.54M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.79M
3
WAT icon
Waters Corp
WAT
+$937K
4
TYRA icon
Tyra Biosciences
TYRA
+$142K

Sector Composition

Rank Sector Weight
1 Healthcare 81.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
51
CALL
Cytokinetics
CYTK
$10.8B
– –
-404,900
Closed -$33.8M
CYTK icon
52
PUT
Cytokinetics
CYTK
$10.8B
– –
-400,500
Closed -$33.4M
GPCR icon
53
PUT
Structure Therapeutics
GPCR
$3.67B
– –
-10,000
Closed -$408K
TYRA icon
54
Tyra Biosciences
TYRA
$1.61B
– –
-10,253
Closed -$142K
WAT icon
55
Waters Corp
WAT
$38.7B
– –
-2,845
Closed -$937K
1 2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 19.71% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
DAC
Dividend Assets Capital Ridgeland, South Carolina $501M AUM 13.71% 1-Year Est. Return
AA
Auxano Advisors Bellevue, Washington $501M AUM 24.15% 1-Year Est. Return

Artia Global Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Artia Global Partners held 55 positions worth $498M, up 45% from $344M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners deployed $62.8M of net new capital in Q1 2024, opening 24 new positions and adding to 13 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Novo Nordisk, an estimated $3.54M trimmed.

  • Artia Global Partners's largest Q1 2024 buy was Vertex Pharmaceuticals: 28,900 shares worth $12.1M.
  • Artia Global Partners added most to Intra-Cellular Therapies Inc. in Q1 2024, an estimated $11.6M increase.
  • Artia Global Partners's biggest Q1 2024 reduction was Novo Nordisk, cutting an estimated $3.54M.
  • Artia Global Partners fully exited BioMarin Pharmaceuticals in Q1 2024, selling an estimated $2.79M.
  • Artia Global Partners's ten largest holdings make up 81% of its $498M portfolio in Q1 2024.
  • Artia Global Partners opened 24 new positions and closed 6 in Q1 2024.
  • Artia Global Partners's portfolio value rose 45% quarter-over-quarter to $498M.

Based on Artia Global Partners's 13F filing for Q1 2024, filed 15 May 2024.